Advertisement

Bijblijven

, Volume 25, Issue 7, pp 34–44 | Cite as

Bevolkingsonderzoek naar darmkanker

  • J. B. M. J. Jansen
  • R. J. F. Laheij
  • L. G. M. van Rossum
Artikel
  • 441 Downloads

samenvatting

Bevolkingsonderzoek met behulp van fecale occult-bloedtesten kan de sterfte aan dikkedarmkanker aanzienlijk terugdringen en is kosteneffectiever dan bevolkingsonderzoek op baarmoederhalskanker of borstkanker. In 2003 heeft de Europese Commissie haar lidstaten daarom geadviseerd om de bevolking te gaan screenen op dikkedarmkanker. Inmiddels wordt in een aantal Europese landen gescreend en zijn al 12 miljoen Europeanen in de leeftijd tussen 50 en 75 jaar onderzocht. In 2005 werd tijdens een consensusbijeenkomst over dit onderwerp geconcludeerd dat ook in ons land aan alle uitgebreide criteria van Wilson en Junger was voldaan of binnen korte tijd kon worden voldaan en werd geadviseerd om de komende tien jaar bij bevolkingsonderzoek gebruik te gaan maken van fecale occult-bloedtesten (FOBT). Vanaf 2006 zijn in de regio Maastricht, Nijmegen, Amsterdam en Rotterdam een aantal proefbevolkingsonderzoeken uitgevoerd, waaruit naar voren is gekomen dat een immunologische fecale occult-bloedtest, de OCSensor®, duidelijk beter is dan de klassieke Hemoccult®-test. Mede op basis van deze resultaten en het advies van een speciale commissie van de Gezondheidsraad, zal de minister binnenkort een besluit nemen om de Nederlandse bevolking te gaan screenen op dikkedarmkanker, waarbij dan geleidelijke invoer van een landelijk bevolkingsonderzoek met een immunologische FOBT het meest waarschijnlijke scenario is.

Literatuur

  1. 1.
    Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-92.Google Scholar
  2. 2.
    Huppe D, Hartmann H, Felten G, Kemen M, Tannapfel A, Gillessen A, et al. [Effectiveness of screening colonoscopy in a community-based study]. Zeitschrift fur Gastroenterologie 2008;46(2):193-200.Google Scholar
  3. 3.
    Segnan N, Senore C, Andreoni B, Azzoni A, Bisanti L, Cardelli A, et al. Comparing attendance and detection rate of colonoscopy with sigmoidoscopy and FIT for colorectal cancer screening. Gastroenterology 2007;132(7):2304-12.Google Scholar
  4. 4.
    Khalid-de Bakker C, Jonkers D, Hameeteman W, Masclee A, Stockbrügger R. Primary colonoscopy screening for colorectal cancer in a workplace-based community: first results of participation and acceptance. Abstractboek NVGE 2007(2):1. www.nvge.nl/archief3.Google Scholar
  5. 5.
    Betes M, Munoz-Navas MA, Duque JM, Angos R, Macias E, Subtil JC, et al. Use of colonoscopy as a primary screening test for colorectal cancer in average risk people. Am J Gastroenterol 2003;98(12):2648-54.Google Scholar
  6. 6.
    Regula J, Rupinski M, Kraszewska E, Polkowski M, Pachlewski J, Orlowska J, et al. Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. N Engl J Med 2006;355(18):1863-72.Google Scholar
  7. 7.
    Terhaar sive Droste JS, Craanen ME, Hulst RWM van der, Bartelsman JF, Bezemer PD, Cappendijk KR, et al. Diagnostic yield of colorectal neoplasia in daily clinical practice: consequences for future colorectal cancer screening? Abstractboek NVGE 2008(1):1. www.nvge.nl/archief3.Google Scholar
  8. 8.
    Balkom BA van, Goedhard JG, Bievre MA de, Bakker CM, Deursen CTBM van, Rijken J, et al. Direct access colonoscopy for general practitioners in the Netherlands is feasible and has a high diagnostic yield. Abstractboek NVGE 2006(1):1. www.nvge.nl/archief3.Google Scholar
  9. 9.
    Rossum LG van, Rijn AF van, Munster IP van, Jansen JB, Fockens P, Laheij RJ, Dekker E. Earlier stages of colorectal cancer detected with immunochemical faecal occult blood tests. Neth J Med 2009;67:182-6.Google Scholar
  10. 10.
    Rossum LG van, Rijn AF van, Laheij RJ, Oijen MG van, Fockens P, Krieken HH van, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008;135(1):82-90. Epub 2008 Mar 25.Google Scholar
  11. 11.
    Visser M de, Ballegooijen M van, Bloemers SM, Deventer SJ van, Jansen JB, Jespersen J, et al. Report on the Dutch consensus development meeting for implementation and further development of population screening for colorectal cancer based on FOBT. Cell Oncol 2005;27(1):17-29.Google Scholar
  12. 12.
    Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993;328(19):1365-71.Google Scholar
  13. 13.
    Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348(9040):1472-7.Google Scholar
  14. 14.
    Faivre J, Tazi MA, El Mrini T, Lejeune C, Benhamiche AM, Dassonville F. Faecal occult blood screening and reduction of colorectal cancer mortality: a case-control study. Br J Cancer 1999;79(3-4):680-3.Google Scholar
  15. 15.
    Faivre J, Dancourt V, Lejeune C, Tazi MA, Lamour J, Gerard D, et al. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology 2004;126(7):1674-80.Google Scholar
  16. 16.
    Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996;348(9040):1467-71.Google Scholar
  17. 17.
    Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005;129(2):422-8.Google Scholar
  18. 18.
    Hol L, Leerdam ME van, Ballegooijen M van, Vuuren AJ van, Reijerink JCI, Togt ACM van der, et al. Screening for colorectal cancer; randomized trial comparing two different forms of faecal occult blood testing and sigmoidoscopy. Gut 2008;57(Supplement):1.Google Scholar
  19. 19.
    Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, Ransohoff DF. Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. N Engl J Med 2000;343(3):169-74.Google Scholar
  20. 20.
    Gondal G, Grotmol T, Hofstad B, Bretthauer M, Eide TJ, Hoff G. The Norwegian Colorectal Cancer Prevention (NORCCAP) screening study: baseline findings and implementations for clinical work-up in age groups 50-64 years. Scand J Gastroenterol 2003;38(6):635-42.Google Scholar
  21. 21.
    Weissfeld JL, Schoen RE, Pinsky PF, Bresalier RS, Church T, Yurgalevitch S, et al. Flexible sigmoidoscopy in the PLCO cancer screening trial: results from the baseline screening examination of a randomized trial. J Natl Cancer Inst 2005;97(13):989-97.Google Scholar
  22. 22.
    Atkin WS, Cook CF, Cuzick J, Edwards R, Nothhover JMA, Wardle J. Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. Lancet 2002;359(9314):1291-300.Google Scholar
  23. 23.
    Thiis-Evensen E, Hoff GS, Sauar J, Langmark F, Majak BM, Vatn MH. Population-based surveillance by colonoscopy: effect on the incidence of colorectal cancer. Telemark Polyp Study I. Scand J Gastroenterol 1999;34(4):414-20.Google Scholar
  24. 24.
    Richardson G, Bloor K, Williams J, Russell I, Durai D, Cheung WY, Farrin A, Coulton S. Cost-effectiveness of nurse delivered endoscopy: Findings from randomised multi-institution nurse endoscopy trials (MINuET). BMJ 2009;338:270.Google Scholar
  25. 25.
    Rabeneck L, Paszat LF, Hilsden RJ, Saskin R, Leddin D, Grunfeld E, et al. Bleeding and perforation after outpatient colonoscopy and their risk factors in usual clinical practice. Gastroenterology 2008;135(6):1899-906, 906 e1.Google Scholar
  26. 26.
    Johnson CD, Chen MH, Toledano AY, Heiken JP, Dachman A, Kuo MD, et al. Accuracy of CT colonography for detection of large adenomas and cancers. N Engl J Med 2008;359(12):1207-17.Google Scholar
  27. 27.
    Fletcher RH. Colorectal cancer screening on stronger footing. N Engl J Med 2008;359(12):1285-7.Google Scholar
  28. 28.
    Rockey DC, Gupta S. Accuracy of CT colonography for colorectal cancer screening. N Engl J Med 2008;359(26):2842; author reply 3-4.Google Scholar
  29. 29.
    Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004;351(26):2704-14.Google Scholar
  30. 30.
    Rossum LGM van, Rijn AF van, Adang EMM, Oijen MGH van, Laheij RJF, Fockens P, et al. Immunochemical faecal occult blood testing is more cost-effective than guaiac faecal occult blood testing and no screening in colorectal cancer screening when implementing randomised controlled data according to intention to screen. Gut 2008;57(Suppl):1.Google Scholar
  31. 31.
    Rossum LGM van, Oijen MGH van, Schuurmans J, Verbeek ALM, Laheij RJF, Jansen JBMJ. Two samples for immunochemical fecal occult blood tests in screening for colorectal cancer: implementation and participation. Abstractboek NVGE 2009(1):1. www.nvge.nl/archief3.Google Scholar
  32. 32.
    Richardson G, Bloor K, Williams J, Russell I, Durai D, Cheung WY, Farrin A, Coulton S. Cost-effectiveness of nurse delivered endoscopy: Findings from randomised multi-institution nurse endoscopy trials (MINuET). BMJ 2009;338:270. Google Scholar

Copyright information

© Bohn Stafleu van Loghum 2009

Authors and Affiliations

  • J. B. M. J. Jansen
    • 1
  • R. J. F. Laheij
  • L. G. M. van Rossum
  1. 1.

Personalised recommendations